Biodesix, Inc. - $BDSX STOCK NEWS

Biodesix announced that it will present new data on the Nodify XL2 test at the 2024 ATS International Conference. The data focuses on the test's ability to identify benign lung nodules in patients with emphysema. The presentation will review a subgroup analysis from the ORACLE study involving 280 patients, demonstrating high negative predictive value of the test, helping to rule out lung cancer irrespective of emphysema status. Dr. Arthur Romero from UNLV will present the findings, suggesting that the test can help avoid unnecessary procedures, thereby allowing timely emphysema treatments.

Biodesix, Inc. (Nasdaq: BDSX) announced first-quarter 2024 results showcasing total revenue of $14.8 million, a 64% year-over-year increase, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume. The company raised $55 million in gross proceeds from a public offering. Biodesix reported a record quarterly gross profit margin of 79% and a Net Loss improvement of 27%. The company aims to reach profitability by growing revenue and maintaining cost discipline.

Biodesix, Inc. (Nasdaq: BDSX) will participate in the 2024 RBCCM Global Healthcare Conference, with CEO Scott Hutton hosting investor meetings. The conference will take place from May 14-15, 2024, in New York, NY. The presentation will be webcast live and available for replay on Biodesix's website.

Biodesix, Inc. (Nasdaq: BDSX) will report its first-quarter 2024 financial results on May 8, 2024. The company, specializing in lung disease diagnostics, will host a conference call and webcast to discuss the results and business update.

Biodesix, Inc. (BDSX) presented new data at the AACR Annual Meeting 2024 showcasing advancements in liquid biopsy technologies for detecting cell-free DNA and the importance of rapid turnaround time in identifying actionable tumor mutations in a real-world clinical setting. The studies included a presentation on single cell and cell-free nucleic acid analyses using a new droplet digital PCR system, as well as real-world assessment of turnaround time for variant testing in NSCLC. An exploratory analysis from the FLAURA2 clinical study sponsored by AstraZeneca was also presented, focusing on the prognostic and predictive nature of EGFR mutations in patients with EGFR-mutated advanced NSCLC receiving first-line osimertinib treatment.

Biodesix, Inc. (BDSX) announces the pricing of its underwritten offering of common stock and concurrent private placement, expecting gross proceeds of $55.0 million. The company plans to convert Series A Non-Voting Convertible Preferred Stock to common stock upon stockholder approval.

Biodesix, Inc. (BDSX) has signed a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center to develop diagnostic tests for cancer treatment. The collaboration aims to create oncology biomarker assays utilizing Biodesix's genomics, proteomics, and data mining capabilities, along with Bio-Rad's digital PCR assay technology. This partnership marks a significant milestone for Biodesix in the field of oncology diagnostics.

Biodesix, Inc. (BDSX) reports impressive financial and operational results for the fourth quarter and fiscal year 2023, showcasing significant growth in Lung Diagnostic test volume, gross profit margin improvement, and strong revenue guidance for 2024. The company achieved a 65% increase in Lung Diagnostic test volume in FY2023, with a 77% gross profit margin in Q4 2023. Total revenue for Q4 2023 was $14.7 million, representing a 52% increase year-over-year. Biodesix anticipates generating $65 to $68 million in total revenue in 2024, indicating a 32% to 39% growth rate.

Biodesix, Inc. (BDSX) CEO, Scott Hutton, will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The presentation will focus on the company's diagnostic solutions for lung disease.